| 1 |
Groenewegen A, Rutten FH, Mosterd A, et al. Epidemiology of heart failure[J]. Eur J Heart Fail, 2020, 22(8): 1342-1356.
|
| 2 |
Ponikowski P, Anker SD, Alhabib KF, et al. Heart failure: preventing disease and death worldwide[J]. ESC Heart Fail, 2014, 1(1)：4-25.
|
| 3 |
Virani SS, Alonso A, Benjamin EJ, et al. Heart disease and stroke statistics-2020 update: a report from the american heart association[J]. Circulation, 2020, 141(9)：139.
|
| 4 |
Green EM, Givertz MM. Management of acute right ventricular failure in the intensive care unit[J]. Curr Heart Fail Rep, 2012, 9(3)：228-235.
|
| 5 |
Kepinska K, Adamczak DM, Kałużna-Oleksy M. Advanced heart failure: a review[J]. Adv Clin Exp Med, 2019, 28(8)：1143-1148.
|
| 6 |
Hardy JD. The first lung transplant in man (1963) and the first heart transplant in man (1964)[J]．Transplant Proc, 1999, 31(1-2): 25-29.
|
| 7 |
Rose AG, Cooper DK. A histopathologic grading system of hyperacute (humoral, antibody-mediated) cardiac xenograft and allograft rejection[J]. J Heart Lung Transplant, 1996, 15(8)：804-817.
|
| 8 |
Morris Thomas. James Hardy and the first heart transplant[J]. Lancet, 2017, 389(10086): 2280-2281.
|
| 9 |
Bailey LL, Nehlsen-Cannarella SL, Concepcion W, et al. Baboon-to-human cardiac xenotransplantation in a neonate[J]. JAMA, 1985, 254(23)：3321.
|
| 10 |
Mccurry KR, Diamond LE, Kooyman DL, et al. Human complement regulatory proteins expressed in transgenic swine protect swine xenografts from humoral injury[J]. Transplant Proc, 1996, 28(2)：758.
|
| 11 |
Mccurry KR, Kooyman DL, Alvarado CG, et al. Human complement regulatory proteins protect swine-to-primate cardiac xenografts from humoral injury[J]. Nat Med, 1995, 1(5)：423-427.
|
| 12 |
Kuwaki K, Knosalla C, Dor F, et al. Suppression of natural and elicited antibodies in pig-to-baboon heart transplantation using a human anti-human CD154 mAb-based regimen[J]. Am J Transplant, 2015, 4(3)：363-372.
|
| 13 |
Mcgregor C, Teotia SS, Byrne GW, et al. Cardiac xenotransplantation: progress toward the clinic[J]. Transplantation, 2004, 78(11)：1569-1575.
|
| 14 |
Wang Y, Lei T, Wei L, et al. Xenotransplantation in China: present status[J]. Xenotransplantation, 2019, 26(1)：12490.
|
| 15 |
Zhong R. Gal knockout and beyond[J]. Am J Transplant, 2007, 7(1): 5-11.
|
| 16 |
Ekser B, Li P, Cooper DKC. Xenotransplantation: past, present, and future[J]. Curr Opin Organ Transplant, 2017, 22(6): 513-521.
|
| 17 |
Cooper DK, Bottino R. Recent advances in understanding xenotransplantation: implications for the clinic[J]. Expert Rev Clin Immunol, 2015, 11(12)：1379-1390.
|
| 18 |
Shu S, Ren J, Song J. Cardiac xenotransplantation: a promising way to treat advanced heart failure[J]. Heart Fail Rev, 2020(1) ：71-91.
|
| 19 |
Reichart B, Lngin M, Radan J, et al. Pig-to-non-human primate heart transplantation: The final step toward clinical xenotransplantation？[J]. J Heart Lung Transplant, 2020, 39(8): 751-757.
|
| 20 |
Chan JL, Mohiuddin MM. Heart xenotransplantation[J]. Curr Opin Organ Transplant, 2017, 22(6): 549-554.
|
| 21 |
Kuwaki K, Tseng YL, Dor FJ, et al. Heart transplantation in baboons using alpha1，3-galactosyltransferase gene-knockout pigs as donors: initial experience[J]. Nat Med, 2005, 11(1): 29-31.
|
| 22 |
Cowan PJ, Robson SC. Progress towards overcoming coagulopathy and hemostatic dysfunction associated with xenotransplantation[J]. Int J Surg, 2015, 23(Part B): 296-300.
|
| 23 |
Ezzelarab MB, Ekser B, Isse K, et al. Increased soluble CD154 (CD40 ligand) levels in xenograft recipients correlate with the development of de novo anti-pig IgG antibodies[J]. Transplantation, 2014, 97(5)：502-508.
|
| 24 |
Cooper DK, Keogh AM, Brink J, et al. Report of the Xenotransplantation Advisory Committee of the International Society for Heart and Lung Transplantation: the present status of xenotransplantation and its potential role in the treatment of end-stage cardiac and pulmonary diseases[J]. J Heart Lung Transplant, 2000, 19(12)：1125-1165.
|
| 25 |
McGregor CG, Davies WR, Oi K, et al. Cardiac xenotransplantation: recent preclinical progress with 3-month median survival[J]. Thorac Cardiovasc Surg, 2005, 130(3): 844-851.
|
| 26 |
Martínez-Comendador J, Marcos-Vidal JM, Gualis J, et al. Subclinical hypothyroidism might increase the risk of postoperative atrial fibrillation after aortic valve replacement[J]. Thorac Cardiovasc Surg, 2016, 64(5)：427-433.
|
| 27 |
Iwase H, Ekser B, Hara H, et al. Thyroid hormone: relevance to xenotransplantation[J]. Xenotransplantation, 2016, 23(4)：293-299.
|
| 28 |
Cascalho M, Platt JL. Xenotransplantation and other means of organ replacement[J]. Nat Rev Immunol, 2001, 1(2)：154-160.
|
| 29 |
Yang YG, Sykes M. Xenotransplantation: current status and a perspective on the future[J]. Nat Rev Immunol, 2007, 7(7)：519-531.
|
| 30 |
Byrne G, Stalboerger PE, Heppelmann C, et al. Proteomic identification of non-Gal antibody targets after pig-to-primate cardiac xenotransplantation[J]. Xenotransplantation, 2010, 15(4): 268-276.
|
| 31 |
Diamond LE, Quinn CM, Martin MJ, et al. A human CD46 transgenic pig model system for the study of discordant xenotransplantation[J]. Transplantation, 2001, 71(1)：132-142.
|
| 32 |
Cozzi E, White D. The generation of transgenic pigs as potential organ donors for humans[J]. Nat Med, 1995, 1(9): 964-966.
|
| 33 |
Fodor WL, Williams BL, Matis LA, et al. Expression of a functional human complement inhibitor in a transgenic pig as a model for the prevention of xenogeneic hyperacute organ rejection[J]. Proc Natl Acad Sci U S A, 1994, 911(23)：11153-11157.
|
| 34 |
Petersen B, Ramackers W, Tiede A, et al. Pigs transgenic for human thrombomodulin have elevated production of activated protein C[J]. Xenotransplantation, 2010, 16(6)：486-495.
|
| 35 |
Lin CC, Ezzelarab M, Hara H, et al. Atorvastatin or transgenic expression of TFPI inhibits coagulation initiated by anti-nonGal IgG binding to porcine aortic endothelial cells[J]. J Thromb Haemost, 2010, 8(9)：2001-2010.
|
| 36 |
Wheeler DG, Joseph ME, Mahamud SD, et al. Transgenic swine: expression of human CD39 protects against myocardial injury[J]. J Mol Cell Cardiol, 2012, 52(5)：958-961.
|
| 37 |
Oropeza M, Petersen B, Carnwath JW, et al. Transgenic expression of the human A20 gene in cloned pigs provides protection against apoptotic and inflammatory stimuli[J]. Xenotransplantation, 2009, 16(6): 522-534.
|
| 38 |
Tena A, Kurtz J, Leonard DA, et al. Transgenic expression of human CD47 markedly increases engraftment in a murine model of pig-to-human hematopoietic cell transplantation[J]. Am J Transplant, 2014, 14(12)：2713-2722.
|
| 39 |
Martin C, Plat M, Véronique Nerrière-Daguin, et al. Transgenic expression of CTLA4-Ig by fetal pig neurons for xenotransplantation[J]. Transgenic Res, 2005, 14(4)：373.
|
| 40 |
Shen Z, Teng X, Qian X, et al. Immunoregulation effect by overexpression of heme oxygenase-1 on cardiac xenotransplantation[J]. Transplant Proc, 2011, 43(5)：1994-1997.
|
| 41 |
Dalmasso AP, Vercellotti GM, Platt JL, et al. Inhibition of complement-mediated endothelial cell cytotoxicity by decay-accelerating factor. Potential for prevention of xenograft hyperacute rejection[J]. Transplantation, 1991, 52(3)：530-533.
|
| 42 |
White DJ, Oglesby T, Liszewski MK, et al. Expression of human decay accelerating factor or membrane cofactor protein genes on mouse cells inhibits lysis by human complement[J]. Transpl Int, 1992, 5(Suppl 1): S648-S650.
|
| 43 |
Zhou H, Hara H, Cooper DKC. The complex functioning of the complement system in xenotransplantation[J]. Xenotransplantation, 2019, 26(4): e12517.
|
| 44 |
Dai Y, Vaught TD, Boone J, et al. Targeted disruption of the alpha1，3-galactosyltransferase gene in cloned pigs[J]. Nat Biotechnol, 2002, 20(3)：251-255.
|
| 45 |
Kolber-Simonds D, Lai L, Watt SR, et al. Production of alpha-1，3-galactosyltransferase null pigs by means of nuclear transfer with fibroblasts bearing loss of heterozygosity mutations[J]. Proc Natl Acad Sci U S A, 2004, 101(19): 7335-7340.
|
| 46 |
Yamada K, Yazawa K, Shimizu A, et al. Marked prolongation of porcine renal xenograft survival in baboons through the use of alpha1，3-galactosyltransferase gene-knockout donors and the cotransplantation of vascularized thymic tissue[J]. Nat Med, 2005，11(1)：32-34.
|
| 47 |
Burlak C, Paris LL, Lutz AJ, et al. Reduced binding of human antibodies to cells from GGTA1/CMAH KO pigs[J]. Am J Transplant, 2014, 14(8): 14(8)：1895-1900.
|
| 48 |
Butler JR, Paris LL, Blankenship RL, et al. Silencing porcine CMAH and GGTA1 genes significantly reduces xenogeneic consumption of human platelets by porcine livers[J]. Transplantation, 2016, 100(3): 571.
|
| 49 |
Tector AJ, Mosser M, Tector M, et al. The possible role of anti-Neu5Gc as an obstacle in xenotransplantation[J]. Front Immunol, 2020, 11：622.
|
| 50 |
Ponticelli C, Banfi G. Thrombotic microangiopathy after kidney transplantation[J]. Transpl Int, 2006, 19(10)：789-794.
|
| 51 |
Robson SC, Cooper DK, D′Apice AJ. Disordered regulation of coagulation and platelet activation in xenotransplantation[J]. Xenotransplantation, 2010, 7(3)：166-176.
|
| 52 |
Aird WC. Endothelium and allotransplantation[J]. Transplantation, 2006, 82(1 Suppl): S6-S8.
|
| 53 |
Ramackers W, Rataj D, Werwitzke S, et al. Expression of human thrombomodulin on porcine endothelial cells can reduce platelet aggregation but did not reduce activation of complement or endothelium - an experimental study[J]. Transpl Int, 2020, 33(4)：437-449.
|
| 54 |
Ezzelarab MB, Isse K, Ekser B, et al. Systemic inflammation in xenograft recipients (SIXR) precedes activation of coagulation in the presence of T cell-directed immunosuppression[J]. Transplantation, 2012, 94(10S): S69.
|
| 55 |
Petersen B, Ramackers W, Lucas-Hahn A. Transgenic expression of human heme oxygenase-1 in pigs confers resistance against xenograft rejection during ex vivo perfusion of porcine kidneys[J]. Xenotransplantation, 2012, 19(3): 355-368.
|
| 56 |
Fischer K, Kraner-Scheiber S, Petersen B, et al. Efficient production of multi-modified pigs for xenotransplantation by "combineering" ，gene stacking and gene editing[J]. Sci Rep, 2016, 6：29081.
|
| 57 |
Hundrieser J, Hein R, Pokoyski C, et al. Role of human and porcine MHC DRB1 alleles in determining the intensity of individual human anti-pig T-cell responses. Xenotransplantation. 2019 Jul；26(4): e12523.
|
| 58 |
Ladowski JM, Reyes LM, Martens GR, et al. Swine leukocyte antigen class Ⅱ is a xenoantigen[J]. Transplantation, 2018, 102(2): 249-254.
|
| 59 |
Cozzi E, Vial C, Ostlie D, et al. Maintenance triple immunosuppression with cyclosporin A, mycophenolate sodium and steroids allows prolonged survival of primate recipients of hDAF porcine renal xenografts[J]. Xenotransplantation, 2010, 10(4)：300-310.
|
| 60 |
Nanno Y, Burlak C. Xenotransplantation literature update, July/August 2020[J]. Xenotransplantation, 2020, 27(6): e12653.
|
| 61 |
Pham MX, Hunt SA, Johnson FL. Cardiac xenotransplantation[J]. Coron Artery Dis, 2004, 15(2): 99-105.
|
| 62 |
Doménech N, Sánchez-Corral P. Xenoantibodies and complement activity determinations by flow cytometry in pig-to-primate xenotransplantation[J]. Methods Mol Biol, 2020, 2110：73-81.
|
| 63 |
Byrne GW, Davies WR, Oi K, et al. Increased immunosuppression, not anticoagulation, extends cardiac xenograft survival[J]. Transplantation, 2006, 82(12)：1787-1791.
|
| 64 |
Mohiuddin MM, Corcoran PC, Singh AK, et al. B-cell depletion extends the survival of GTKO.hCD46Tg pig heart xenografts in baboons for up to 8 months[J]. Am J Transplant, 2012, 12(3)：763-771.
|
| 65 |
Abicht JM, Mayr T, Reichart B, et al. Pre-clinical heterotopic intrathoracic heart xenotransplantation: a possibly useful clinical technique[J]. Xenotransplantation, 2016, 22(6)：427-442.
|
| 66 |
Cooper D, Ezzelarab MB, Hara H, et al. The pathobiology of pig-to-primate xenotransplantation: a historical review[J]. Xenotransplantation, 2016, 23(2)：83-105.
|
| 67 |
Iwase H, Ezzelarab MB, Ekser B, et al. The role of platelets in coagulation dysfunction in xenotransplantation, and therapeutic options[J]. Xenotransplantation, 2014, 21(3)：201-220.
|
| 68 |
Fishman JA. Infection in xenotransplantation: opportunities and challenges[J]. Curr Opin Organ Transplant, 2019, 24(5)：527-534.
|
| 69 |
Fishman JA. Infectious disease risks in xenotransplantation[J]. Am J Transplant, 2018, 18(8): 1857-1864.
|
| 70 |
Denner J. Porcine lymphotropic herpesviruses (PLHVs) and xenotranplantation[J]. Viruses, 2021, 13(6)：1072.
|
| 71 |
Denner J. Recombinant porcine endogenous retroviruses (PERV-A/C): a new risk for xenotransplantation？[J]. Arch Virol, 2008, 153(8)：1421-1426.
|
| 72 |
Güell M. Genome-wide PERV inactivation in pigs using CRISPR/Cas9[J]. Methods Mol Biol, 2020, 2110：139-149.
|
| 73 |
刘永锋，郑树森. 器官移植学[M]. 北京：人民卫生出版社，2014.
|
| 74 |
Cooper D, Gollackner B, Sachs DH. Will the pig solve the transplantation backlog？[J]. Annual Review of Medicine, 2002, 53(1)：133-147.
|
| 75 |
Lu T, Yang B, Wang R, et al. Xenotransplantation: current status in preclinical research[J]. Front Immunol, 2020, 10：3060.
|
| 76 |
Onions D, Cooper DK, Alexander TJ, et al. An approach to the control of disease transmission in pig-to-human xenotransplantation[J]. Xenotransplantation, 2000, 7(2)：143-155.
|
| 77 |
Center for Biologics Evaluation and Research. Xenotransplantation guidances-guidance for industry: source animal, product, preclinical, and clinical issues concerning the use of xenotransplantation products in humans[EB/OL]．(2016-12)[2022-02-24].
URL
|
| 78 |
Pierson RN 3rd, Burdorf L, Madsen JC, et al. Pig-to-human heart transplantation: Who goes first？[J]. Am J Transplant, 2020, 20(10): 2669-2674.
|
| 79 |
Hong SH, Kim HJ, Kang SJ, et al. Novel immunomodulatory approaches for porcine islet xenotransplantation[J]. Curr Diab Rep, 2021, 21(1): 3.
|
| 80 |
Cooper D, Wijkstrom M, Hariharan S, et al. Selection of patients for initial clinical trials of solid organ xenotransplantation[J]. Transplantation, 2016, 101(7)：1551-1558.
|
| 81 |
Dew MA, DiMartini AF, Dobbels F, et al. The 2018 ISHLT/APM/AST/ICCAC/STSW recommendations for the psychosocial evaluation of adult cardiothoracic transplant candidates and candidates for long-term mechanical circulatory support[J]. J Heart Lung Transplant, 2018, 37(7): 803-823.
|